原始来源记录

pembrolizumab · NCT06295731 注册更新

状态: ACTIVE_NOT_RECRUITING → RECRUITING; 主要完成: 2029-05 → 2029-12; 完成: 2029-05 → 2031-05; 入组: 410 → 450; 主要结局: ['Phase 2: Objective Response Rate (ORR)', 'Phase 3: Progression-Free Survival (PFS)', 'Phase 3: Overall Survival (OS)'] → ['Phase 2: Objective Response Rate by investigator (ORRinv)', 'Phase 3: Progression-Free Survival by Investigator (PFSinv)', 'Phase 3: Overall Survival (OS)']; 国家: {'total_sites': 87, 'us_sites': 25} → {'total_sites': 89, 'us_sites': 26}